Dr Mosi’s PhD studies involved the mechanism of reaction of two alpha glycosyltransferases, glycogen phosphorylase and cyclodextrin glycosyltransferase, through the use of modified substrates and inhibitors. Dr Mosi is a senior research scientist with eight years’ experience in pharmaceutical drug research. She has developed and implemented novel assays for the purpose of the identification of inhibitors of metallo-enzymes as antibacterials and inhibitors of cysteine proteases for the treatment of cancer. Dr Mosi has applied expertise in enzymology, receptor based cell biology, drug metabolism and protein purification and production. As well, she has designed and standardized systems and procedures for interpreting scientific results. She also has a sound knowledge of FDA guidelines and is trained in GLP and GMP procedures. Dr Mosi is a past member of the Drug Information Association, International Society for the Study of Xenobiotics, Society for Biomolecular Screening, American Society of Microbiology, and the Canadian Society of Chemistry. As first author of 10 published, peer reviewed manuscripts, and as editor of numerous other papers in fields of biology, biochemistry, chemistry and pharmacology, Dr Mosi brings an extensive writing background to her editing work for Edanz Editing.